MCIM
ADMS

Meadow Creek Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Meadow Creek Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,704
Closed -$94K – 1395
2018
Q3 		$94K Buy
+4,704
New +$110K ﹤0.01% 1232

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Meadow Creek Investment Management's ADMS Position: Q4 2018 in Review

Meadow Creek Investment Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 4,704 shares — an estimated $94K sold.

Meadow Creek Investment Management first reported a position in ADMS in Q3 2018 and held it in 1 quarter. The position peaked at $94K in Q3 2018. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • Meadow Creek Investment Management reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Meadow Creek Investment Management sold 4,704 Adamas Pharmaceuticals shares in Q4 2018, an estimated $94K.
  • Meadow Creek Investment Management first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Meadow Creek Investment Management's Adamas Pharmaceuticals position peaked at $94K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Meadow Creek Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.